PRIMARY AND SALVAGE CHEMOTHERAPY IN ADVANCED HODGKINS-DISEASE - THE MILAN-CANCER-INSTITUTE EXPERIENCE

被引：53

作者：

BONADONNA, G ^{[1
]}

SANTORO, A ^{[1
]}

GIANNI, AM ^{[1
]}

VIVIANI, S ^{[1
]}

SIENA, S ^{[1
]}

BREGNI, M ^{[1
]}

ZUCALI, R ^{[1
]}

LOMBARDI, F ^{[1
]}

BONFANTE, V ^{[1
]}

GIANNI, L ^{[1
]}

VALAGUSSA, P ^{[1
]}

机构：

[1] IST NAZL TUMORI,DIV FOOD SCI,I-20133 MILAN,ITALY

来源：

ANNALS OF ONCOLOGY | 1991年 / 2卷

关键词：

HODGKINS DISEASE; CHEMOTHERAPY;

D O I：

10.1093/annonc/2.suppl_1.9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This paper reviews the most relevant therapeutic results achieved by the Milan Cancer Institute through successive randomized studies in advanced Hodgkin's disease. The experience achieved confirms the therapeutic importance of an anthracycline-containing regimen such as ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) as salvage treatment and as primary chemotherapy, either when combined with irradiation or cyclically alternated with MOPP (mechlorethamine/vincristine/procarbazine/prednisone). Anthracyline-based combinations can be further refined to decrease toxicity. The biologic aspects of drug-sensitive nu drug-resistant tumor cells and the accurate definition of prognostic categories at the time of first treatment failure are also discussed.

引用

页码：9 / 16

页数：8

共 29 条

[1] ANDERSON JR, 1990, IN PRESS ANN ONCOL
[2] BONADONNA G, 1982, CANCER RES, V42, P4309
[3] ALTERNATING NON-CROSS-RESISTANT COMBINATION CHEMOTHERAPY OR MOPP IN STAGE-IV HODGKINS-DISEASE - A REPORT OF 8-YEAR RESULTS
BONADONNA, G
VALAGUSSA, P
SANTORO, A
[J]. ANNALS OF INTERNAL MEDICINE, 1986, 104 (06) : 739 - 746
[4] INFLUENCE OF CLINICAL-TRIALS ON CURRENT TREATMENT STRATEGY FOR HODGKINS-DISEASE
BONADONNA, G
VALAGUSSA, P
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 19 (01): : 209 - 218
[5] BONADONNA G, 1975, CANCER, V36, P252, DOI 10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO
[6] 2-7
[7] CANELLOS GP, 1990, SEMIN ONCOL, V17, P2
[8] DRUG-RESISTANCE IN MULTIPLE-MYELOMA AND NON-HODGKINS LYMPHOMA - DETECTION OF P-GLYCOPROTEIN AND POTENTIAL CIRCUMVENTION BY ADDITION OF VERAPAMIL TO CHEMOTHERAPY
DALTON, WS
GROGAN, TM
MELTZER, PS
SCHEPER, RJ
DURIE, BGM
TAYLOR, CW
MILLER, TP
SALMON, SE
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (04) : 415 - 424
[9] DEVITA VT, 1983, CANCER, V51, P1209, DOI 10.1002/1097-0142(19830401)51:7<1209::AID-CNCR2820510707>3.0.CO
[10] 2-J

← 1 2 3 →